Company intelligence / Profile preview

Selfapy

Berlin*†, Berlin, Germanyselfapy.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Selfapy offers CE-certified, clinically validated digital therapeutics for mental health conditions. Its programs are guideline-based and have demonstrated efficacy in multiple randomized controlled trials. The products are permanently listed as reimbursed DiGA in Germany and available by prescription with costs covered by statutory health insurance.

Therapeutic areas: PsychiatryNeurology
Modalities: Non-pharmacological therapyDevice (as a CE-certified digital therapeutic app)Digital therapeutic (dTx)
Industry: Digital Health Medical Devices

Drug pipeline

6 assets

Selfapy Depression

Commercial

Indications: Depression

5 more assets in the full pipeline.

Request access →

Partnerships

SHS Capital and other healthcare investors prior to acquisition; now integrated with MEDICE Health Family's portfolio

Beyond the preview

Go deeper on Selfapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selfapy.

Explore the full profile